Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma

Completed

Brief Summary: Real-world evidence study to assess the safety and effectiveness of XEN® Glaucoma Treatment System in Chinese patients with refractory glaucoma. Participants will be (prospective) or have already been (retrospective) implanted with XEN via specific urgent medical need.

Recruitment & Eligibility

Inclusion Criteria

Patients with refractory glaucomas, including cases where previous surgical treatment has failed, cases of POAG, and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy

Exclusion Criteria

Angle closure glaucoma where angle has not been surgically opened
Previous glaucoma shunt/valve in the target quadrant
Presence of conjunctival scarring, prior conjunctival surgery or other conjunctival pathologies (eg, pterygium) in the target quadrant
Active inflammation (eg, blepharitis, conjunctivitis, keratitis, uveitis)
Active iris neovascularization or neovascularization of the iris within six months of the surgical date
Anterior chamber intraocular lens
Presence of intraocular silicone oil
Vitreous present in the anterior chamber

Arm && Interventions

Group	Intervention	Description
XEN Glaucoma Stent	XEN Glaucoma Stent	-

Primary Outcome Measures

Name	Time	Method
Percentage of patients achieving at least a 20% reduction from intraocular pressure (IOP) while on the same number or fewer number of IOP lowering medications than at baseline	Baseline to Month 12

Secondary Outcome Measures

Name	Time	Method
Mean decrease in IOP	Baseline to Month 12

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial